-
Moderna NASDAQ:MRNA Moderna, Inc is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based on messenger RNA.
Location: 200 Technology Sq, Massachusetts, 02139-3578, US | Website: www.modernatx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
9.303B
Cash
6.867B
Avg Qtr Burn
-801.8M
Short % of Float
10.89%
Insider Ownership
9.52%
Institutional Own.
71.70%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
mRESVIA (mRNA-1345) Details Respiratory syncytial virus | Approved Update | |
Spikevax® Details COVID-19 | Approved Quarterly sales | |
mRNA-1273 Details COVID-19 | Approved Quarterly sales | |
mRNA-1010 Details Influenza | BLA Submission | |
mRNA-1403 Details Norovirus, Gastroenteritis | Phase 3 Data readout | |
mRNA-4157/V940 +KEYTRUDA Details Melanoma, Cancer | Phase 3 Data readout | |
mRNA-4157/V940 +KEYTRUDA Details Cancer, Non-small cell lung carcinoma | Phase 3 Data readout | |
mRNA-1647 Details Cytomegalovirus | Phase 3 Data readout | |
mRNA-1083 Details COVID-19, Influenza | Phase 3 Update | |
mRNA-1283 Details COVID-19 | Phase 3 Update | |
mRNA-3705 Details Rare diseases, Methylmalonic acidemia | Phase 1/2 Data readout | |
mRNA-1468 Details Varicella-zoster virus | Phase 1/2 Data readout | |
mRNA-3927 Details Propionic acidemia | Phase 1/2 Update | |
mRNA-1574 Details Human immunodeficiency virus | Phase 1 Data readout |